e-Drug3D

1924

DACOMITINIB

INN
DACOMITINIB

cas 1110813-31-4

CLASS

ANTINEOPLASTIC
IRREVERSIBLE KINASE INHIBITOR OF EGFR FAMILY (EGFR/HER1, HER2 AND HER4)
COMPLEX PDB 4I23
TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
ALSO INHIBITED THE ACTIVITY OF DDR1, EPHA6, LCK, DDR2, AND MNK1 AT CLINICALLY RELEVANT CONCENTRATIONS

ROUTE (list)

ORAL

ATC code

L01EB07

PK parameters

F 80 PERCENT
Tmax 6 HOUR
VD 1889 LITER
Cl 24.9 LITER / HOUR
PPB 98 PERCENT
t1/2 70 HOUR

Target

TARGET EGFR KINASE

DrugCentral

Epidermal growth factor receptor UNIPROT P00533 EGFR

Receptor tyrosine-protein kinase erbB-2 UNIPROT P04626 ERBB2

Download SDF file

2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-

Formula:
C24H25ClFN5O2

Calculated chemical properties:

MW 469.94
NB_atoms 33
XLogP 5.16
PSA 72.381
NB_HD 2
NB_HA 7
fsp3 0.29
Lipinski(0=no;1=yes) 0

FDA
NDA 211288 (label) INN (DACOMITINIB) VIZIMPRO (PFIZER) APPROVAL= AP YEAR= 2018 NEWMOLECULARENTITY